The U.S. Food and Drug Administration on Tuesday cleared Lembaz (adrabetadex) injection, the first therapy shown to help people with a severe form of Niemann-Pick disease type C live longer, according to the agency.

The FDA said the approval is for reducing the risk of death in adults and children who weigh at least 7 kilograms (about 15 pounds) and whose neurological symptoms started before age 6, a group the agency describes as having infantile-onset Niemann-Pick disease type C (NPC). Acting FDA Commissioner Kyle Diamantas, J.D., said, “For the first time, there is a treatment shown to help adults and children with this serious disease live longer.”

NPC is a rare, inherited lysosomal storage disease that the FDA estimates affects about 1 in 150,000 people, in which cholesterol and other fats build up inside cells. The agency said the buildup, especially in the brain, leads to worsening neurological problems, such as loss of movement, coordination and swallowing. According to the FDA, cases that begin before age 6 are the most severe.

Before this action, two therapies had approval for NPC, but the FDA said neither had been shown to cut the risk of death. The agency also said both have age and weight limits that restrict use in the youngest and sickest patients. Lembaz is the first FDA-approved option to lower the risk of death for adults and children with infantile-onset NPC who weigh at least 7 kilograms, the agency said.

A trained health care provider gives Lembaz as an injection into the space around the spinal cord, known as an intrathecal injection, every two weeks, according to the FDA.

To assess survival, the FDA reviewed data on 36 Lembaz-treated patients from three clinical trials plus an expanded access program. All had neurological symptoms that began before age 6, the agency said. Compared with a matched external control group, patients who received Lembaz lived longer, with a 55% reduction in the risk of death, according to the FDA. The agency said median survival was 8.5 years in the Lembaz group and 4.9 years in the control group. The FDA said this survival benefit was seen whether or not patients were also on miglustat, a drug used off label in NPC.

The most frequent side effects include problems with hearing, balance and coordination, fatigue, vomiting, back pain, headache, fever, diarrhea, nausea and cough, the FDA said. Lembaz includes a boxed warning about hearing problems, including the risk of permanent hearing loss, according to the agency. The FDA said patients should have a full hearing check before starting treatment and on a regular basis during therapy, and dose changes may be needed based on those results.

The FDA said Lembaz received Breakthrough Therapy designation. The agency granted approval to Mandos, LLC, a subsidiary of Beren Therapeutics, PBC.